Bio-Rad Laboratories Q2 FY26: revenue $651.0M, flat; diluted EPS $13.85

Key figures from this report

These are the numbers Bio-Rad Laboratories reported for Q2 FY26, the quarter ended Jun 30, 2026, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

1. Revenue$651.0MFlat against $651.6M in Q2 FY2510-Q income statement, on EDGAR
2. Net income$371.4M+17% from $317.8M in Q2 FY2510-Q income statement, on EDGAR
3. Diluted EPS$13.85+19% from $11.67 in Q2 FY2510-Q income statement, on EDGAR
4. Cash and cash equivalents$517.0M+40% from $369.3M in Q2 FY25Cash and equivalents only; the company page adds short-term investments.10-Q balance sheet, on EDGAR
5. Cash from operations$98.7M−15% from $116.5M in Q2 FY2510-Q cash flow statement, on EDGAR; the filing reports year-to-date cash flows; this quarter is the year-to-date total less the earlier quarters

Every quarter in the financial tables